研究单位：[1]University of Oxford[2]The First Affiliated Hospital of Kunming Medical College Kunming,Yunnan,China,650032[3]The First People's Hospital of Yunnan ProvinceKunming,Yunnan,China,650032[4]The Second Affiliated Hospital of Kunming Medical College Kunming,Yunnan,China,650101[5]People's Hospital of Yuxi CityYuxi,Yunnan,China,653100[6]First Affiliated Hospital of the Medical College Shihezi,Xinjiang,China,832008[7]Xin Jiang Traditional Chinese Medicine Hospital Urumqi,Xinjiang,China,830000[8]Zhe Jiang Hospital Hangzhou,Zhejiang,China,310013
The purpose of this study is to determine whether acarbose therapy can reduce cardiovascular-related morbidity and mortality in patients with impaired glucose tolerance (IGT) who have established coronary heart disease (CHD) or acute coronary syndrome (ACS). A secondary objective of the study is to determine if acarbose therapy can prevent or delay transition to type 2 diabetes mellitus (T2DM) in this patient population.
